PRESS RELEASE

Sienna expands Clinical Advisory Board

Melbourne, Australia, 16 March 2020: Sienna Cancer Diagnostics (ASX:SDX) has appointed Professor Geoff McCaughan to its recently formed Clinical Advisory Board.

Professor McCaughan is Head of the Liver Injury & Cancer Program at the Centenary Institute, University of Sydney. After completing his postdoctoral training at the University of Oxford in 1986 as a CJ Martin Fellow, he returned to Sydney where he developed the basic research program for the AW Morrow Gastroenterology and Liver Centre at Royal Prince Alfred Hospital of which he is now the Director.

Sienna is building a Clinical Advisory Board that will provide the company with access to invaluable advice and expertise to develop and commercialise its cancer diagnostic tests. Professor McCaughan joins US-based urologist Dr Raoul Concepcion on Sienna's Clinical Advisory Board.

Sienna's CEO and Managing Director, Carl Stubbings said: "Professor McCaughan is an eminent gastroenterologist. His clinical experience, together with that of Dr Concepcion, will be enormously valuable in guiding the company's development of new tests, including the previously announced development of a test for pancreatic cancer."

Professor McCaughan said: "I am very excited to be working with the Sienna team. My focus has always been to improve clinical outcomes for patients and I believe the development of tests that aid in the early diagnosis of cancers, such as pancreatic cancer, will be a critical step in fulfilling that objective."

ENDS.

For Further Information, please contact:
Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 8288 2141

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia. Sienna's strengths lie in the identification, development and commercialisation of novel IVD technologies that satisfy an unmet clinical / market need. The Company has taken its first product, an IVD test for the biomarker hTERT, from research, through development, manufacturing, product registration, and market launch through a growing network of distribution partners.

The Company is focused on growing revenues from the existing product, increasing market access through new distribution partners, extending the applications for their hTERT test, and expanding their product offerings with the addition of new technologies into the product development pipeline.

Sienna's most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples. The sample preparation technology, known as SIEN-NET™, can more accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.